Northern Trust
KYTX icon

Northern Trust’s Kyverna Therapeutics KYTX Stock Holding History

Northern Trust’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$674K Buy
78,042
+26,470
+51% +$221K ﹤0.01% 3494
2025
Q4 		$485K Sell
51,572
-106
-0.2% -$787 ﹤0.01% 3666
2025
Q3 		$310K Hold
51,678
– – ﹤0.01% 3817
2025
Q2 		$159K Sell
51,678
-139,986
-73% -$346K ﹤0.01% 4003
2025
Q1 		$370K Sell
191,664
-4,030
-2% -$11.9K ﹤0.01% 3693
2024
Q4 		$732K Buy
195,694
+61,757
+46% +$296K ﹤0.01% 3518
2024
Q3 		$655K Buy
133,937
+93,447
+231% +$720K ﹤0.01% 3495
2024
Q2 		$304K Buy
40,490
+11,697
+41% +$179K ﹤0.01% 3695
2024
Q1 		$715K Buy
+28,793
New +$803K ﹤0.01% 3437

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Northern Trust's KYTX Position: Q1 2026 in Review

Northern Trust increased its Kyverna Therapeutics (KYTX) stake by 51% in Q1 2026, buying an estimated $221K and bringing the position to 78,042 shares worth $674K. The position accounts for ﹤0.01% of the portfolio, ranked #3494.

Northern Trust first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $732K in Q4 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Northern Trust held 78,042 shares of Kyverna Therapeutics worth $674K as of Q1 2026.
  • Northern Trust bought 26,470 Kyverna Therapeutics shares in Q1 2026, an estimated $221K.
  • Kyverna Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3494 holding.
  • Northern Trust first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Northern Trust's Kyverna Therapeutics position peaked at $732K in Q4 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.